Normal Immunoglobulin

Product Details:

Sections

Overview

Immune globulin products from human plasma were first used in 1952 to treat primary immune deficiency. Intravenous immunoglobulin (IVIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors.

IVIGs are sterile, purified IgG products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM). [1] Initially, immune globulin products were administered by intramuscular injection. One of biggest advances with IVIG in recent years has been the use of sorbitol-based formulations as opposed to sucrose-based formulations, which allow for IV administration with fewer reactions. [2, 3]  IVIG was initially shown to be effective in immune thrombocytopenic purpura (ITP) in 1981. [4] There are now multiple alternative IVIG preparations available for intravenous administration that have been approved by the US Food and Drug Administration (FDA) for the treatment of primary humoral immunodeficiencies and chronic immune thrombocytopenic purpura.  Also, a liquid, pasteurized, 10% concentrated intravenous gammaglobulin preparation is as effective as a 5% concentrated preparation, making the concentrated versions more convenient to administer.
Supporting universal healthcare with affordable exports from India.Certifications and ComplianceAll our exports are backed by WHO-GMP, ISO, and DCGI approvals.